HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
4-(4'-chlorobenzyloxy)benzyl nicotinate
structure given in first source
Also Known As:
KCD 232; KCD-232
Networked:
3
relevant articles (
1
outcomes,
0
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Pyridines: 88
Nicotinic Acids: 13
4-(4'-chlorobenzyloxy)benzyl nicotinate: 3
Heterocyclic Acids
Nicotinic Acids: 13
4-(4'-chlorobenzyloxy)benzyl nicotinate: 3
Related Diseases
1.
Hypertriglyceridemia
05/01/1985 - "
These results suggest that 1. DR-induced hypercholesterolemia is due to both an increased Ch synthesis in the liver and delayed clearance of Ch from the circulation; 2. DR-induced hypertriglyceridemia is caused by both an increased hepatic FA synthesis and depressed TG hydrolysis in the circulation; 3. KCD-232 improves the hypercholesterolemia by inhibiting the elevated Ch synthesis and Ch absorption from the gut; and 4. KCD-232 improves the hypertriglyceridemia by inhibiting the elevated hepatic FA synthesis and by stimulating both hepatic FA oxidation and TG hydrolysis activity in the circulation.
"
05/01/1985 - "
KCD-232 improved the hypercholesterolemia and hypertriglyceridemia of DR-treated rats.
"
05/01/1985 - "
Mechanisms for hypercholesterolemia and hypertriglyceridemia and the effects of KCD-232, a new hypolipidemic agent, on them were studied in male Wistar rats with daunorubicin (DR)-induced nephrosis.
"
2.
Hypercholesterolemia
05/01/1985 - "
These results suggest that 1. DR-induced hypercholesterolemia is due to both an increased Ch synthesis in the liver and delayed clearance of Ch from the circulation; 2. DR-induced hypertriglyceridemia is caused by both an increased hepatic FA synthesis and depressed TG hydrolysis in the circulation; 3. KCD-232 improves the hypercholesterolemia by inhibiting the elevated Ch synthesis and Ch absorption from the gut; and 4. KCD-232 improves the hypertriglyceridemia by inhibiting the elevated hepatic FA synthesis and by stimulating both hepatic FA oxidation and TG hydrolysis activity in the circulation.
"
05/01/1985 - "
KCD-232 improved the hypercholesterolemia and hypertriglyceridemia of DR-treated rats.
"
05/01/1985 - "
Mechanisms for hypercholesterolemia and hypertriglyceridemia and the effects of KCD-232, a new hypolipidemic agent, on them were studied in male Wistar rats with daunorubicin (DR)-induced nephrosis.
"
3.
Nephrosis
05/01/1985 - "
Mechanisms for hypercholesterolemia and hypertriglyceridemia and the effects of KCD-232, a new hypolipidemic agent, on them were studied in male Wistar rats with daunorubicin (DR)-induced nephrosis.
"
4.
Hyperlipidemias (Hyperlipidemia)
05/01/1985 - "
[Experimental nephrotic hyperlipidemia induced in rats by daunorubicin and effects of KCD-232[4-(4'-chlorobenzyloxy)benzyl nicotinate] on lipid metabolism].
"
5.
Hepatomegaly
03/01/1987 - "
Hepatomegaly was induced by clofibrate, CGA, KCD-232 and MLM-160.
"
Related Drugs and Biologics
1.
Hypolipidemic Agents (Antihyperlipidemics)
2.
Lipoproteins (Lipoprotein)
3.
Daunorubicin (Cerubidine)
4.
Clofibrate
5.
oxidized low density lipoprotein
6.
nicotinic acid benzyl ester
Related Therapies and Procedures
1.
Oral Administration